Skip to main content
Clinical Trials/NCT01922388
NCT01922388
Completed
N/A

Early Versus Late Application of Subthalamic Deep Brain Stimulation to Parkinson's Disease Patients With Motor Complications: a Multicentre, Prospective and Observational Study

Chen Ling1 site in 1 country200 target enrollmentAugust 2013

Overview

Phase
N/A
Intervention
Not specified
Conditions
Parkinson Disease
Sponsor
Chen Ling
Enrollment
200
Locations
1
Primary Endpoint
Changes in 39-item Parkinson's disease questionnaire (PDQ-39) scores
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Although deep brain stimulation of the subthalamic nucleus(STN DBS) has become the surgical treatment of choice for Parkinson's disease(PD), a consensus on the timing of surgery is lacking. This study is intended to demonstrate that early, compared with delayed, introduction of STN DBS is more beneficial for PD patients who have developed motor complications.

Detailed Description

In this prospective study, 200 PD patients will be recruited for STN DBS over three years, including 133 with motor complications existing for more than three years (late complication group) and 67 less than three years (early complication group). To make a comparison of therapeutic efficacy between the two groups, motor and non-motor symptoms will be assessed using specific rating scales and questionnaires.

Registry
clinicaltrials.gov
Start Date
August 2013
End Date
December 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Chen Ling
Responsible Party
Sponsor Investigator
Principal Investigator

Chen Ling

MD, PhD

First Affiliated Hospital, Sun Yat-Sen University

Eligibility Criteria

Inclusion Criteria

  • Idiopathic Parkinson's Disease with good response to levodopa(i.e. more than 30% improvement in the MDS-UPDRS Part III score after an acute levodopa challenge)
  • Presence of fluctuations and/or dyskinesias
  • Age ranging from 18 to 75 years old
  • Normal brain MRI
  • Absence of dementia (Mini Mental State Examination ≥ 26)
  • Absence of severe psychiatric diseases
  • Written informed consent

Exclusion Criteria

  • Presence of severe metabolic diseases
  • Severe cardiac/respiratory/renal/hepatic diseases
  • Secondary parkinsonism or multiple system atrophy
  • Illiteracy or insufficient language skills to complete the questionnaires
  • Poor compliance and unreasonable expectation
  • Women who are pregnant or breast feeding
  • Simultaneous participation in another clinical trial

Outcomes

Primary Outcomes

Changes in 39-item Parkinson's disease questionnaire (PDQ-39) scores

Time Frame: From baseline to 4 years

Quality of life

Secondary Outcomes

  • Changes in time spent in the "on" state without troubling dyskinesia based on Parkinson's disease home diary(From baseline to 4 years)
  • Changes in Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores(From baseline to 4 years)
  • Severe adverse effects(From baseline to 4 years)
  • Changes in MDS-UPDRS patient questionnaire (Part I B and Part II) scores(From baseline to 4 years)

Study Sites (1)

Loading locations...

Similar Trials